title: [Renal protective effects of benidipine and valsartan in primary hypertension patients with proteinuria].
abstract: OBJECTIVE
  To compare the renal protective effects between calcium channel blocker benidipine and angiotensin II receptor blocker valsartan in primary hypertension patients with proteinuria.
  
  
  METHODS
  A total of 236 patients were divided to low (< 1 g/24 h) and high (1 - 3 g/24 h) proteinuria groups and treated with benidipine (8 mg/d) or valsartan (80 mg/d) for 48 weeks. Blood pressure, glomerular filtration rate (GFR) and 24 h protein were measured at baseline, 12, 24 and 48 weeks.
  
  
  RESULTS
  Blood pressure was significantly and equally reduced in all treated groups (all P < 0.05 vs. baseline). GFR was also significantly and equally improved in all treated groups after 24 weeks treatments (all P < 0.05 at 24 weeks and 48 weeks). Proteinuria reduction at 24 and 48 weeks was more significant in patients treated with valsartan compared to patients treated with benidipine in low proteinuria group [24 weeks: (0.27 +/- 0.07) g/24 h vs. (0.39 +/- 0.06) g/24 h, P < 0.01; 48 weeks: (0.18 +/- 0.01) g/24 h vs. (0.30 +/- 0.05) g/24 h, P < 0.01].
  
  
  CONCLUSIONS
  The renal protection efficacy of valsartan and benidipine was similar in primary hypertensive patients with proteinuria.
authors.affiliation: Department of Nephrology, Qilu Hospital of Shandong University, Jinan 250012, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Peng
authors.forename: Zhao
authors.initials: Z
authors.lastname: Hu
authors.forename: Ling
authors.initials: L
authors.lastname: Guo
authors.forename: Xiang-dong
authors.initials: XD
authors.lastname: Yang
authors.forename: Qing
authors.initials: Q
authors.lastname: Xia
authors.forename: Xian-hua
authors.initials: XH
authors.lastname: Li
authors.forename: Bei
authors.initials: B
authors.lastname: Jiang
authors.forename: Fei
authors.initials: F
authors.lastname: Pei
authors.forename: Jian
authors.initials: J
authors.lastname: Song
mesh_terms: D000328:Adult; D000368:Aged; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000627:therapeutic use*; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000150:complications / Q000188:drug therapy*; D013777:Tetrazoles / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D057911:Angiotensin Receptor Antagonists; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D013777:Tetrazoles; C061004:benidipine; D000068756:Valsartan; D014633:Valine